13,036 Shares in Danaher Co. (NYSE:DHR) Acquired by TriaGen Wealth Management LLC

TriaGen Wealth Management LLC acquired a new position in Danaher Co. (NYSE:DHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,036 shares of the conglomerate's stock, valued at approximately $3,624,000. Danaher accounts for approximately 1.2% of TriaGen Wealth Management LLC's portfolio, making the stock its 14th largest holding.

A number of other hedge funds also recently bought and sold shares of DHR. Tsfg LLC lifted its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate's stock worth $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher during the 2nd quarter valued at $25,000. nVerses Capital LLC bought a new position in Danaher in the 2nd quarter worth $25,000. Redmont Wealth Advisors LLC purchased a new position in Danaher during the first quarter valued at $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in Danaher during the second quarter valued at about $51,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Trading Up 0.9 %

DHR stock traded up $2.40 during midday trading on Friday, reaching $274.38. 1,949,849 shares of the company traded hands, compared to its average volume of 2,717,951. The firm has a market capitalization of $203.23 billion, a price-to-earnings ratio of 46.51, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The business has a 50 day moving average of $270.72 and a 200-day moving average of $260.02. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business's revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. As a group, sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher's dividend payout ratio is currently 18.31%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on DHR shares. Robert W. Baird lifted their price objective on Danaher from $271.00 to $278.00 and gave the company an "outperform" rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $280.00 price objective for the company. Barclays lifted their target price on shares of Danaher from $270.00 to $285.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 24th. Leerink Partners upped their price objective on Danaher from $275.00 to $280.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 24th. Finally, The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the stock a "neutral" rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $282.12.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the business's stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company's stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company's stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company's stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.